Browsing by Author "Sicinska, Ewa"

Now showing items 1-4 of 4

    • Altered Chromosomal Topology Drives Oncogenic Programs in SDH-Deficient GISTs 

      Flavahan, William A.; Drier, Yotam; Johnstone, Sarah E.; Hemming, Matthew; Tarjan, Daniel R.; Hegazi, Esmat; Shareef, Sarah; Javed, Nauman; Eschle, Benjamin K.; Gokhale, Prafulla C.; Hornick, Jason; Sicinska, Ewa; Demetri, George; Bernstein, Bradley (Springer Science and Business Media LLC, 2019-10-16)
      Epigenetic aberrations are widespread in cancer, yet the underlying mechanisms and causality remain poorly understood1-3. A subset of gastrointestinal stromal tumors (GISTs) lack canonical kinase mutations but instead have ...

    • Enhancer Signatures Stratify and Predict Outcomes of Non-Functional Pancreatic Neuroendocrine Tumors 

      Cejas, Paloma; Drier, Yotam; Brosens, Lodewijk A. A.; Deshpande, Vikram; Morsink, Folkert H. M.; Graham, Mindy K.; Valk, Gerlof D.; Vriens, Menno R.; Fernandez-Del Castillo, Carlos; Fabiana Lucia da Silva, Annacarolina; Font-Tello, Alba; Heaphy, Christopher M.; Sicinska, Ewa; Dreijerink, Koen; Epstein, Charles; Conemans, Elfi; Ferrone, Cristina; Adar, Tomer; Bowden, Michaela; Whitton, Holly; Long, Henry; Gaskell, Elizabeth; Shoresh, Noam; Kulke, Matthew; Chung, Daniel; Bernstein, Bradley; Shivdasani, Ramesh (Springer Science and Business Media LLC, 2019-07-01)
      Most pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are therefore considered ‘non-functional’. As clinical behaviors vary widely and distant metastases are eventually lethal, biological ...

    • A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis 

      Zadra, Giorgia; Photopoulos, Cornelia; Tyekucheva, Svitlana; Heidari, Pedram; Weng, Qing Ping; Fedele, Giuseppe; Liu, Hong; Scaglia, Natalia; Priolo, Carmen; Sicinska, Ewa; Mahmood, Umar; Signoretti, Sabina; Birnberg, Neal; Loda, Massimo (Backwell Publishing Ltd, 2014)
      5′AMP-activated kinase (AMPK) constitutes a hub for cellular metabolic and growth control, thus representing an ideal therapeutic target for prostate cancers (PCas) characterized by increased lipogenesis and activation of ...

    • Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma 

      Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T.; Anatone, Alex J.; Sicinska, Ewa T.; Fletcher, Jonathan A.; Demetri, George D.; Wagner, Andrew J. (Impact Journals LLC, 2016)
      Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced ...